

Genetic Testing for Hereditary Cardiomyopathy

Last Review Date: October 12, 2018

Number: MG.MM.LA.33C3

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

<p>Familial hypertrophic cardiomyopathy (HCM)</p>	<p>A disease of the myocardium commonly caused by a mutation in one or more of the cardiac sarcomere genes and characterized by left ventricular hypertrophy (LVH) in the absence of predisposing cardiac or systemic diseases. The clinical features of HCM vary for each individual and range from asymptomatic to progressive heart failure to sudden cardiac death. Common symptoms include dyspnea on exertion, palpitations, chest pain, orthostatic hypotension, presyncope, and syncope. It is the most common hereditary cardiac condition in the U.S., affecting 1 in 500 adults and possibly the most common cause of sudden cardiac death (SCD) in young athletes and others 35 years of age and younger.</p>
<p>Familial dilated cardiomyopathy (DCM)</p>	<p>A type of dilated cardiomyopathy associated with heterogenous genetic mutations, characterized by left ventricular enlargement and dilatation, systolic dysfunction, leading to clinical manifestations of heart failure. Primary clinical manifestations of DCM are heart failure, arrhythmias and/or conduction system disease, and/or thromboembolic disease.</p>
<p>Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C)</p>	<p>A myocardial disorder of the right ventricle associated with a heterogenous number of genetic mutations including PKP2 (plakophilin-2), DSG2 (desmoglein-2) and DSP (desmoplakin) genes. ARVD/C is characterized by progressive fibrofatty replacement of the myocardium that predisposes affected individuals to ventricular tachycardia and sudden death, especially in young persons and athletes. The pathology in ARVD/C may also extend to involve the left ventricle.</p>

Guideline

Genetic testing for HCM is considered medically necessary when the following criteria are met; **all**:

1. Member has a first-degree relative with a documented history of HCM, and the first degree relative also has a genetic mutation with strong evidence for pathogenicity
2. Member tests negative for HCM with specific clinical investigations (e.g., with EKG, echocardiogram or cardiac magnetic resonance imaging [MRI])
3. Member has received genetic counseling

Limitations/Exclusions

1. Genetic testing for HCM is considered investigational for all other indications not meeting the above criteria.
2. Genetic testing for all other hereditary cardiomyopathies including, DCM, ARVD/C, restrictive and left ventricular noncompaction cardiomyopathies is considered investigational and not medically necessary for all indications.

Applicable Procedure Codes

81403	Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of 10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) (Revision eff. 01/01/2018)
81405	Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis) CPOX (coproporphyrinogen oxidase) (eg, hereditary coproporphyrinuria), full gene sequence CTSC (chymotrypsin C) (eg, hereditary pancreatitis), full gene sequence PKLR (pyruvate kinase, liver and RBC) (eg, pyruvate kinase deficiency), full gene sequence (Revision eff. 01/01/2018)
81406	Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence HMBS (hydroxymethylbilane synthase) (eg, acute intermittent porphyria), full gene sequence PPOX (protoporphyrinogen oxidase) (eg, variegate porphyria), full gene sequence (Revision eff. 01/01/2018)
81407	Molecular pathology procedure, Level 8 (eg, analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform)
81479	Unlisted molecular pathology procedure
S3865	Comprehensive gene sequence analysis for hypertrophic cardiomyopathy
S3866	Genetic analysis for a specific gene mutation for hypertrophic cardiomyopathy (HCM) in an individual with a known HCM mutation in the family

Applicable ICD-10 Diagnosis Codes

I42.0	Dilated cardiomyopathy
I42.1	Obstructive hypertrophic cardiomyopathy
I42.2	Other hypertrophic cardiomyopathy

References

1. Ackerman MJ, Priori SG, Willems S, et al. Heart Rhythm Society/European Heart Rhythm Association (HRS/EHRA) Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. *Heart Rhythm*. 2011; 8(8):1308-1339.
2. BlueCross BlueShield Association (BCBSA), Technology Evaluation Center (TEC). Genetic testing for predisposition to inherited hypertrophic cardiomyopathy. TEC Assessment Program. Chicago, IL: BCBSA; August 2010
3. Brodsky GL, Muntoni F, Miodini S et al. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. *Circulation* 2000; 101(5):473-6.
<http://circ.ahajournals.org/content/101/5/473.full.pdf+html>. Accessed October 16, 2018.
4. Calkins H. Arrhythmogenic right-ventricular dysplasia/cardiomyopathy. *Curr Opin Cardiol*. 2006;21(1):55-63.
5. Cirino AL, Ho C. Familial hypertrophic cardiomyopathy overview. *Gene Reviews*. Last updated May 17, 2011.
<http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=hyper-card>. Accessed October 16, 2018.

6. Corrado D, Basso C, Thiene G. Arrhythmogenic right ventricular cardiomyopathy: Diagnosis, prognosis, and treatment. *Heart*. 2000;83(5):588-595. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy -- a Heart Failure Society of America Practice Guideline. *J Card Fail*. 2009;15(2):83-97.
7. Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2011.
<http://circ.ahajournals.org/content/124/24/2761>. Accessed October 16, 2018.
8. Gollob MH, Blier L, Brugada R, et al. Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. *Can J Cardiol*. 2011; 27(2):232-245.
9. Hershberger, R. E., Lindenfeld, J., Mestroni, L., Seidman, C. E., Taylor, M. R. G., & Towbin, J. A. (2009). Genetic evaluation of cardiomyopathy - a Heart Failure Society of America practice guideline. *Journal of Cardiac Failure*, 15 (2), 83-97.
10. Hershberger RE M, A. Dilated Cardiomyopathy Overview. *GeneReviews* September 2015.
<http://www.ncbi.nlm.nih.gov/books/NBK1309/>. Accessed October 16, 2018.
11. Hirtle-Lewis, M., Desbiens, K., Ruel, I., Rudzicz, N., Genest, J., Engert, J. C., et al. (2013). The genetics of dilated cardiomyopathy: A prioritized candidate gene study of LMNA, TNNT2, TCAP, and PLN. *Clinical Cardiology*, 36 (10), 628-633.
12. Hudecova K, Simkova I, Gardlik R, Bernadic M. Genetic screening of patients with hypertrophic cardiomyopathy -- a new diagnostic strategy for risk stratification? *Bratisl Lek Listy*. 2009;110(2):85-92.
13. Lakdawala NK, Funke BH, Baxter S et al. Genetic testing for dilated cardiomyopathy in clinical practice. *J Card Fail* 2012; 18(4):296-303. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666099/>. Accessed October 16, 2018.
14. Maron BJ, Moller JH, Seidman CE, et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: Hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. A statement for healthcare professionals from the Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Basic Science, American Heart Association. *Circulation*. 1998;98:1460-1471.
15. McNally E, MacLeod H, Dellefave L. Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy, Autosomal Dominant. National Center for Biotechnology Information (NCBI). *Gene Reviews*. Last updated January 9, 2014. <http://www.ncbi.nlm.nih.gov/books/NBK1131/>. Accessed October 16, 2018.